143 Views

Laboratory Validation of Pillar’s oncoReveal® Myeloid Panel on the Illumina MiSeq i100 to Deliver Rapid Front-Line NGS for Heme Malignancies

Wednesday, November 12, 2025

10:00 AM - 10:50 AM EST

Location: 159, Level 1

Corporate Workshop Speaker(s)

SH

Sarah Herlihy, Ph.D.

Assistant Director Assay Development
University of Pennsylvania Health System, Pennsylvania, United States
EN

Emmanuel Naouri

Senior Director, Product Management, NGS Mid-Throughput Systems
Illumina, Inc.
AL

AmandaSue Landi

Genomic Development Specialist II
University of Pennsylvania Health System

To help deliver on the promise of precision medicine in oncology, clinical laboratories are looking to more efficiently and effectively deliver rapid, localized next-generation sequencing (NGS) testing to their referring physicians. By decreasing assay turnaround times (TAT) for cancer patients from weeks to just a few days, treatment strategies can be accelerated, and outcomes can potentially be improved. To-date, however, this has been challenged by the historical speed, efficiency and overall costs of performing NGS testing in-house. This workshop will be reviewing the evaluation, clinical validation and implementation of Pillar Biosciences oncoReveal (RUO) NGS panels on the new Illumina MiSeq i100 by a leading academic medical center to successfully deliver simple, rapid, front-line NGS testing for myeloid neoplasms.